Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer

Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer

Abstract Many clinical trials are being conducted to clarify effective combinations of various drugs for immune checkpoint blockade (ICB) therapy. However, although extensive studies from multiple aspects have been conducted regarding treatments for pancreatic ductal adenocarcinoma (PDAC), there are...

Full description

Bibliographic Details
Main Authors: Ari Hashimoto, Haruka Handa, Soichiro Hata, Akio Tsutaho, Takao Yoshida, Satoshi Hirano, Shigeru Hashimoto, Hisataka Sabe
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Cell Communication and Signaling
Subjects:
ARF6
AMAP1
eIF4A inhibitor
Anti-PD-1 therapy
Online Access:https://doi.org/10.1186/s12964-021-00733-y

Internet

https://doi.org/10.1186/s12964-021-00733-y

Similar Items